BACKGROUND: Accurate preoperative and postoperative risk assessment has been critical for counseling patients regarding radical prostatectomy for clinically localized prostate cancer. In addition to other treatment modalities, neoadjuvant or adjuvant therapies have been considered. The growing literature suggested that the experience of the surgeon may affect the risk of prostate cancer recurrence. The purpose of this study was to develop and internally validate nomograms to predict the probability of recurrence, both preoperatively and postoperatively, with adjustment for standard parameters plus surgeon experience. METHODS: The study cohort included 7,724 eligible prostate cancer patients treated with radical prostatectomy by 1 of 72 surgeons. For each patient, surgeon experience was coded as the total number of cases conducted by the surgeon before the patient's operation. Multivariable Cox proportional hazards regression models were developed to predict recurrence. Discrimination and calibration of the models was assessed following bootstrapping methods, and the models were presented as nomograms. RESULTS: In this combined series, the 10-year probability of recurrence was 23.9%. The nomograms were quite discriminating (preoperative concordance index, 0.767; postoperative concordance index, 0.812). Calibration appeared to be very good for each. Surgeon experience seemed to have a quite modest effect, especially postoperatively. CONCLUSIONS: Nomograms have been developed that consider the surgeon's experience as a predictor. The tools appeared to predict reasonably well but were somewhat little improved with the addition of surgeon experience as a predictor variable. (c) 2009 American Cancer Society.
BACKGROUND: Accurate preoperative and postoperative risk assessment has been critical for counseling patients regarding radical prostatectomy for clinically localized prostate cancer. In addition to other treatment modalities, neoadjuvant or adjuvant therapies have been considered. The growing literature suggested that the experience of the surgeon may affect the risk of prostate cancer recurrence. The purpose of this study was to develop and internally validate nomograms to predict the probability of recurrence, both preoperatively and postoperatively, with adjustment for standard parameters plus surgeon experience. METHODS: The study cohort included 7,724 eligible prostate cancerpatients treated with radical prostatectomy by 1 of 72 surgeons. For each patient, surgeon experience was coded as the total number of cases conducted by the surgeon before the patient's operation. Multivariable Cox proportional hazards regression models were developed to predict recurrence. Discrimination and calibration of the models was assessed following bootstrapping methods, and the models were presented as nomograms. RESULTS: In this combined series, the 10-year probability of recurrence was 23.9%. The nomograms were quite discriminating (preoperative concordance index, 0.767; postoperative concordance index, 0.812). Calibration appeared to be very good for each. Surgeon experience seemed to have a quite modest effect, especially postoperatively. CONCLUSIONS: Nomograms have been developed that consider the surgeon's experience as a predictor. The tools appeared to predict reasonably well but were somewhat little improved with the addition of surgeon experience as a predictor variable. (c) 2009 American Cancer Society.
Authors: Andrew J Stephenson; Michael W Kattan; James A Eastham; Zohar A Dotan; Fernando J Bianco; Hans Lilja; Peter T Scardino Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Andrew J Vickers; Fernando J Bianco; Mithat Gonen; Angel M Cronin; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino Journal: Eur Urol Date: 2008-01-14 Impact factor: 20.096
Authors: Steven C Ames; Winston W Tan; Gretchen E Ames; Ronald L Stone; Thomas D Rizzo; Michael G Heckman; Julia E Crook; Matthew M Clark; Teresa A Rummans; Chudley E Werch Journal: J Psychosoc Oncol Date: 2008
Authors: Eric A Klein; Fernando J Bianco; Angel M Serio; James A Eastham; Michael W Kattan; J Edson Pontes; Andrew J Vickers; Peter T Scardino Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Andrew J Vickers; Fernando J Bianco; Angel M Serio; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino Journal: J Natl Cancer Inst Date: 2007-07-24 Impact factor: 13.506
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: M R Danzig; S Kotamarti; R A Ghandour; M B Rothberg; B P Dubow; M C Benson; K K Badani; J M McKiernan Journal: Prostate Cancer Prostatic Dis Date: 2014-11-18 Impact factor: 5.554
Authors: Rochelle Payne Ondracek; Michael W Kattan; Christine Murekeyisoni; Changhong Yu; Eric C Kauffman; James R Marshall; James L Mohler Journal: J Natl Compr Canc Netw Date: 2016-11 Impact factor: 11.908
Authors: Chin-Lee Wu; Brock E Schroeder; Xiao-Jun Ma; Christopher J Cutie; Shulin Wu; Ranelle Salunga; Yi Zhang; Michael W Kattan; Catherine A Schnabel; Mark G Erlander; W Scott McDougal Journal: Proc Natl Acad Sci U S A Date: 2013-03-26 Impact factor: 11.205